Since the beginning of the pandemic, the novel coronavirus (SARS-CoV-2) has infected
approximately 635 million individuals and caused almost 6.5 million deaths worldwide. KUISCID researchers analyzed the neutralizing antibody response among transplant patients who were immunosuppressed. Their study “BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac” was published in “Viruses”.
